Leaderboard

En | De
No articles selected!     View Cart  
You are here: Oncology » Urologic Neoplasms 14. October 2026
Search
medline.ch
Urologic Neoplasms
Advanced search
Dermatology
Endocrinology
Nutrition
Gastroenterology
Gynecology
Haematology
Infectious diseases
Cardiovascular Diseases
Musculoskeletal Diseases
Neurology
Oncology
Musculoskeletal System
Blood
Endocrine System
Gynecologic Neoplasms
Skin
Gastrointestinal
ORL
Respiratory Tract
Urologic Neoplasms
CNS
ORL
Pediatrics
Psychiatry
Respiratory Tract
Sports
Urology-Nephrology
Rect Top
Zoom: Zoom In Zoom Out

   Page 1 of 9107  Previews Next
   
   Articles 1 - 20 / 182132  
   
Urinary Extracellular Vesicle-Associated EphA2 Predicts Intravesical Recurrence in Bladder Cancer.
Int J Urol
Hashimoto M, Tomiyama E, Inoki L, Miki K, Nakayama T, Fujimoto S, Toyoda S, Kikuchi T, Ukekawa R, Yamamoto Y, Minami T, Yoshimura K, Nonomura N, Fujita K.
PMID: 42866931 [PubMed - indexed for MEDLINE]


Complementary Diagnostic Value of ZEB1 and CK7 in Renal Oncocytoma and Chromophobe Renal Cell Carcinoma.
Appl Immunohistochem Mol Morphol
Filipovi, Soldatovi, , Dun, Jevti, Nikoli, Vukajlovi, Radojevi.
PMID: 42866914 [PubMed - as supplied by publisher]


Filling the information gap: a validated comparison of ChatGPT, Gemini, and Claude for penile cancer patient education.
Transl Androl Urol
Yang J, Bushati Y, Lorger S, Saad J, Rathore P.
PMID: 42866825 [PubMed]


Comparative outcomes of radical prostatectomy, radiotherapy, and radiotherapy plus androgen deprivation therapy for high-risk and very high-risk prostate cancer: a narrative review.
Transl Androl Urol
Tun KH, Xiong X, Xu H, Yang L.
PMID: 42866815 [PubMed]


Enhancing intravesical bladder cancer therapy: from mucoadhesive to targeted drug delivery strategies.
Front Med (Lausanne)
Sahini H, Anzengruber M, Lächelt U.
PMID: 42865741 [PubMed]


Neoadjuvant disitamab vedotin (RC-48) plus a PD-1 inhibitor in muscle-invasive bladder cancer: a multicenter real-world study with stratification by HER2 expression and tertiary lymphoid structures.
Front Immunol
Rao XP, Zou XC, Liu X, Xu LY, Huang JB, Yuan YY, Chen T, Zeng T.
PMID: 42865476 [PubMed - indexed for MEDLINE]


Clinical Markers of Vulnerability for Bleeding in Men With Prostate Cancer and Antithrombotic Treatment.
Cancer Rep (Hoboken)
Björkhem-Bergman L, Hedman C, Szilcz M, Frisk G.
PMID: 42865304 [PubMed - indexed for MEDLINE]


Impact of Prior Holmium Laser Enucleation of the Prostate on Outcomes After Robot-Assisted Radical Prostatectomy.
Int J Urol
Nishino T, Shimbo M, Oguchi T, Sano M, Narimoto K, Hattori K, Endo F.
PMID: 42865148 [PubMed - indexed for MEDLINE]


Factors Associated With Trifecta and Pentafecta Achievement in Robot-Assisted Laparoscopic Partial Nephrectomy for Highly Complex Renal Tumors.
Int J Urol
Ishihara H, Nishimura K, Kobari Y, Fukuda H, Yoshida K, Kondo T, Takagi T.
PMID: 42865126 [PubMed - indexed for MEDLINE]


Nanomedicines for prostate cancer therapy: stimuli-responsive design and disease-specific applications.
Chem Commun (Camb)
Ma Y, Song Z, Yang C, Zhang L.
PMID: 42865093 [PubMed - as supplied by publisher]


Transurethral ultrasound ablation (TULSA) for prostate cancer: a systematic review and meta-analysis.
BJU Int
Wang E, Wei X, Dua Y, Perera M, Grummet J.
PMID: 42864969 [PubMed - as supplied by publisher]


Association of Travel Time With Definitive Prostate Cancer Treatment: A United States Registry Cohort Study.
Cancer Med
Dagnino F, Korn S, Daniels D, Qian Z, Stelzl D, Zurl H, Pohl K, Hsieh MC, Hernandez BY, Piccolini A, Lughezzani G, Buffi NM, Lipsitz SR, Reich A, Weissman JS, Cole AP, Trinh QD, Iyer HS.
PMID: 42864849 [PubMed - indexed for MEDLINE]


The role of IFNLR1 in modulating T cell infiltration and cancer progression in renal cell carcinoma.
J Transl Med
Zheng Y, Wang Y, Zhang M, Zhao M, Zhao X, Cao F, Sun M.
PMID: 42864662 [PubMed - indexed for MEDLINE]


Neutropenia events with androgen receptor pathway inhibitor-containing versus control therapies in prostate cancer patients: a systematic review and meta-analysis.
BMC Cancer
Zhang J, Zhang A, Tian J, Wang S, Xiao M.
PMID: 42864616 [PubMed - indexed for MEDLINE]


(177)Lu-Prostate-specific Membrane Antigen Prior to Stereotactic Ablative Radiotherapy in Oligorecurrent Prostate Cancer: Secondary and Exploratory End Point Results from the Randomized Phase 2 LUNAR Trial.
Eur Urol
Kishan AU, Wilhalme H, Felix C, Enke J, Ali FZ, Nabong R, Juarez-Casillas JE, Flores K, Ma TM, Ludwig V, Nakayama M, Ells Z, Dahlbom M, Lauria M, Meyer C, Cao M, Weidhaas JB, Telesca D, McGreevy K, Nickols NG, Parmisano S, Brisbane W, Marks L, Singer AE, Rettig MB, Reiter RE, Valle LF, Allen-Auerbach M, Czernin J, Steinberg ML, Calais J.
PMID: 42864228 [PubMed - as supplied by publisher]


Perioperative immune-based treatment for cisplatin-eligible muscle-invasive bladder cancer: a meta-analysis of randomized controlled trials.
Crit Rev Oncol Hematol
Mollica V, Rosellini M, Giannatempo P, Gupta S, Grande E, Rizzo A, Ricci C, Piazza P, Contieri R, Cattabriga A, Schiavina R, Santoni M, Massari F.
PMID: 42863770 [PubMed - as supplied by publisher]


Ultrasound-controlled therapeutics for bladder cancer: Mechanisms, recent advances, and future perspectives.
Colloids Surf B Biointerfaces
Loke YL, Lim XY, Beishenaliev A, Goh SJ, Dian Z, Leo BF, Kah JCY, Misran M, Nagai T, Imae T, Chik Z, Chung LY, Teo YY, Ong TA, Hwang DW, Kiew LV.
PMID: 42863296 [PubMed - as supplied by publisher]


Real-World HRR Testing Pathways and Patterns of Detected Alterations in Prostate Cancer From the Multinational ARON-3 Study.
Prostate
Incorvaia L, Mollica V, Fiala O, Fujita K, Ürün Y, Melichar B, Molina-Cerrillo J, Alonso-Gordoa T, Basso U, Bourlon MT, Seront E, Giorgi U, Fita MJJ, Rescigno P, Taha T, Maluf FC, Poprach A, Summa S, Buchler T, Galli L, Kopecky J, Aurilio G, Kucharz J, Messina C, Polho GB, Scagliarini S, Grillone F, Bastos DA, Formisano L, Spinelli GP, Mosca A, Rizzo A, Bamias A, Monteiro FSM, Soares A, Massari F, Armstrong AJ, Santoni M.
PMID: 42862920 [PubMed - as supplied by publisher]


Impact of a dietary and exercise intervention on health-related quality of life of prostate cancer patients on active surveillance with overweight/obesity: a secondary analysis of a randomized controlled trial.
Support Care Cancer
Zhu A, Schenk JM, Gulati R, Beatty SJ, VanDoren M, Lin DW, Porter MP, Morrissey C, Dash A, Gore JL, Etzioni R, Plymate SR, Neuhouser ML, Wright JL.
PMID: 42862393 [PubMed - indexed for MEDLINE]


Stage-specific prognostic value of PSA in prostate cancer: a multicentre KAMU-ON study.
World J Urol
Iwamoto H, Izumi K, Machioka K, Toriumi R, Shima T, Nozaki M, Hori T, Inaba T, Nakagawa R, Kamijima T, Kadomoto S, Makino T, Naito R, Yaegashi H, Shigehara K, Nohara T, Miyagi T, Seto C, Kadono Y, Mizokami A.
PMID: 42862366 [PubMed - indexed for MEDLINE]


   
   Articles 1 - 20 / 182132    Page 1 of 9107  Previews Next

 
Rect Bottom
Adserver Footer
 

  Time frame  
   

Sky right 1